COMMUNIQUÉS West-GlobeNewswire

-
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
10/04/2024 -
Kura Oncology to Participate in Stifel Targeted Oncology Forum
10/04/2024 -
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/04/2024 -
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10/04/2024 -
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
10/04/2024 -
Theratechnologies présente ses résultats financiers et fait le point sur ses activités commerciales pour le premier trimestre de l’exercice 2024
10/04/2024 -
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
10/04/2024 -
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10/04/2024 -
BioPorto A/S Appoints Chief Legal Officer
10/04/2024 -
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
10/04/2024 -
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
10/04/2024 -
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10/04/2024 -
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit CLMBR at FIBO Global Fitness, the World's Largest Trade Show for Fitness, Wellness and Health on April 11-14
10/04/2024 -
Immuron Travelan® sales continued strong growth
10/04/2024 -
Ouma Health reaches milestones in solving maternity care challenges for Managed Care Organizations
10/04/2024 -
RadNet to Make its Second Acquisition in Houston, Texas
10/04/2024 -
Medicines360 Appoints Erica Rogers to Board of Directors
10/04/2024 -
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10/04/2024 -
EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device
10/04/2024
Pages